

Bachem AG and GlyTech, Inc. Announce Co-promotion Agreement

Bubendorf/Basel, October 7, 2014 – Bachem (SIX: BANB) the leading peptide manufacturer, and GlyTech Inc. (Kyoto, Japan), the world-leading developer of glycosylated drugs, announced today that they have entered into a co-promotion agreement for GlyTech’s glycosylation technology. As part of the agreement, Bachem will leverage its sales and marketing resources to enhance GlyTech’s partnering efforts and GlyTech will promote Bachem as the partner of choice for manufacture of its glycopeptides and glycoproteins.

GlyTech’s glycosylation technology permits the synthesis of peptides and proteins with pre-attached sugars, selected from a proprietary library of over 50 specific glycans. It has been shown to markedly improve drug properties such as half-life, binding affinity and selectivity. Furthermore, compared to recombinant products, the chemically synthesized proteins are more homogeneous.

Bachem Holding AG and GlyTech Inc. were 2013 CPhI innovation prize finalists for the groundbreaking work on Interferon β -1a. The technology has been used in multiple other projects, such as to manufacture glycosylated somatostatin analogues and glycosylated GLP-1. In all cases, drug improvements were achieved.

“Working together with GlyTech on synthetic Interferon β -1a paved the way to a more profound partnership. The pioneering aspect of developing peptides and proteins with improved properties for our clients and the partnering involved is very much in line with our strategic focus.” said Thomas Früh, CEO of Bachem.

“Bachem has been an ideal collaborator for us and our technology, and we are excited to expand our relationship that enables us to reach a broader set of potential partners for our glycosylation technology,” said Mr. Asai, President and CEO of GlyTech.

About Bachem

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides

About GlyTech, Inc.

GlyTech is a world leader in glycotecnology, having established the large-scale manufacturing process for highly purified and characterized human type N-glycans as well as the chemical synthesis of glycosylated compounds, especially glycopeptides and glycoproteins. GlyTech's technologies can contribute to developing better and lower-cost biopharmaceuticals. GlyTech expects to play a significant role in developing bio-betters, biosimilars, and innovative biopharmaceutical products.

Contact:

For further questions, please visit our websites or contact the person below.

Bachem Holding AG
Stephan Schindler, CFO
Tel.: +41 61 935 2333
Fax: +41 61 935 2324
ir@bachem.com
www.bachem.com

GlyTech, Inc.
Katsura Torii, CBDO
Tel.: +81 75 315 9218
Fax: +81 75 315 9225
glytech-info@glytech.jp
www.glytech.jp